Abstract 119P
Background
Gastric cancer (GC) remains the fifth most common malignancy worldwide accounting for over 1 million new cases and an estimated 769,000 deaths by 2020. Nearly 40% of the global GC cases occur in China, and the 5-year overall survival rate is less than 50%. Lymph node metastases (LNM) is an independent risk factor for prognosis and determines which treatments can be used in GC. LNM plays a crucial gateway role in cancer spread, but the underlying roles of LNM remain controversial, and there is no worldwide consensus. Therefore, the aim of this study was to investigate the clinical perspective and significance of LNM in GC via a retrospective study.
Methods
This study was performed on 129 patients who had gastric cancer with lymphadenectomy for the radical cure, whose specimens were obtained during surgery. Dissected lymph nodes were collected in groups and histopathological studies were performed to detect the lymph node metastasis and metastatic lymph node ratio (MLR). We also analyzed the relationships between rates of lymph node metastasis and tumor diameters, tumor localization, infiltrating depth, histological category, Borrmann typing, and so on.
Results
Among 129 patients with gastric cancer, lymph node metastases were found in 80 patients (62.02%) with a total collection of 3295 lymph nodes and an average of 25.54 lymph nodes per patient. The number of lymph nodes with metastasis was 889. Lymph node metastasis was associated with tumor size, the depth of invasion, Borrmann type, location and histological type. There were correlations between the total number of lymph nodes from 129 gastric cancer patients, metastatic lymph node numbers and MLR. Analysis of the survival curve showed that the survival time and rate had a negative correlation with the TNM stage and MLR.
Conclusions
According to the clinical and pathological factors, the characteristics of lymph node metastasis by groups and stations in different areas, and properly choosing and extending the extent of lymph node resection, the objective of the radical cure for gastric cancer could be achieved individually when radical lymphadenectomy is performed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Technology Innovation Guidance Special Program of Shaanxi Province (2022QFY01-08), Key Research and Development Program of Shaanxi Province (2021SF-288), Natural Science Basic Research Program of Shaanxi Province (2020JQ-950, 2022JM-570), Health Research Program of Shaanxi Province (2022D002).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
Presenter: Qingbao Cheng
Session: Poster viewing 02
89P - Radiotherapy followed by camrelizumab for unresectable biliary tract cancer: A phase II clinical trial
Presenter: Zhenwei Peng
Session: Poster viewing 02
90P - Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma
Presenter: Georges Azzi
Session: Poster viewing 02
92P - Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: A pre-specified analysis of the TALENTop study
Presenter: Huichuan Sun
Session: Poster viewing 02
93P - Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Takuji Okusaka
Session: Poster viewing 02
94P - The treatment burden of neoadjuvant carboplatin/paclitaxel versus 5-fluorouracil/cisplatin in combination with radiotherapy for patients with esophageal cancer
Presenter: Chun-Ling Chi
Session: Poster viewing 02
95P - Additional survival follow-up of TACTICS-L: Transcatheter arterial chemoembolization therapy (TACE) in combination strategy with lenvatinib in (LEN) patients with unresectable hepatocellular carcinoma in Japan
Presenter: Yoshitaka Inaba
Session: Poster viewing 02
96P - Preoperative chemotherapy flot vs dox in patients of locally advanced gastric adenocarcinoma
Presenter: POORNIMA DEVI UTHAYAKUMAR
Session: Poster viewing 02
97P - BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma
Presenter: Nai-Jung Chiang
Session: Poster viewing 02